Guest Speaker

Ximena Arcila-Londono, MD
Platform Trial Site Principal Investigator
Henry Ford Hospital, Detroit MI
HENRY FORD HOSPITAL

Located in Detroit’s Midtown our hospital was founded by automotive pioneer Mr. Henry Ford in 1915

We are one of the largest U.S. teaching hospitals, level 1 trauma center, and an 877 tertiary care hospital

We celebrate the diversity of our employees and patients
We mentor medical students from Wayne State University

As part of Henry Ford Health System, we entered into a 30 year partnership with Michigan State University (MSU):

“In a landmark partnership that will last for at least 30 years, both institutions are committed to aligning efforts across key departments and programs to achieve critical health care and educational goals, while addressing social issues that impact health outcomes for patients in Michigan and beyond.”
HENRY FORD NEUROMUSCULAR TEAM

We treat a variety of conditions including ALS, myasthenia gravis, neuropathy, myopathies, etc.

We have state of the art electrodiagnostic labs in 6 different locations.

We have board certified neurophysiology fellowship.
HARRY J HOENSELAAR ALS CLINIC

- Certified as an ALS Center of Excellence by the ALS association since 1988

- We are a known and respected referral ALS center in southwest Michigan

- We followed more than 300 ALS patients in our multidisciplinary ALS clinic last year

Ximena Arcila, MD
Daniel S. Newman, MD
Kara Steijlen, MD
Our Multidisciplinary team includes: 2 neuromuscular/ALS specialists, 3 pulmonologists, Respiratory Therapist, nursing, Physical and Occupational Therapy, Speech language pathologist, dietician, research team, ALS clinic coordinator.

We offer our patients the possibility to participate in clinical research.

Beverly Duthie, RN, CRC
Kate Swiftney, RN
Anne Vallis
The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial

**Regimen A**
- Placebo
- Verdiperstat
- CNM-Au8
- Zilucoplan
- Pridopidine
- Trehalose
- Shared Placebo

**Regimen B**
- Placebo
- Verdiperstat
- CNM-Au8
- Zilucoplan
- Pridopidine
- Trehalose
- Shared Placebo

**Regimen C**
- Placebo
- Verdiperstat
- CNM-Au8
- Zilucoplan
- Pridopidine
- Trehalose
- Shared Placebo

**Regimen D**
- Placebo
- Verdiperstat
- CNM-Au8
- Zilucoplan
- Pridopidine
- Trehalose
- Shared Placebo

**Regimen E**
- Placebo
- Verdiperstat
- CNM-Au8
- Zilucoplan
- Pridopidine
- Trehalose
- Shared Placebo

3:1 Randomization within each Regimen

(n=160 for each regimen)

(n=120 for active drug; n=40 for placebo)
Study Results Timelines – Regimens A-D

*** Note: COVID-19 might impact these estimates

Q1 → Q2 → Q3 → Q4

LPLV

(Last Participant Last Visit in the Randomized, Placebo Controlled Period)

Database Lock

Top Line Results → Study Reports

Expected LPLV: March-July 2022 (depending on the regimen and OLE choice)
Expected Database Lock: May-Sept 2022
Top Line Results: July-Sept 2022
Study Reports: Oct-Dec 2022

as of 2/10/22
Regimen E Site Activation

Activated!
- Lehigh Valley Health Network - activated!
- Mass General Hospital - activated!
- University of Kansas - activated!
- University of Maryland - activated!
- California Pacific Medical Center - activated!
- Northwestern University - activated!
- Virginia Commonwealth University - activated!

Sites closest to activation:
- University of Nebraska
- University of Cincinnati
- Spectrum Health
- University of Colorado
- Georgetown University
- Barrow Neurological Institute
- Indiana University
- University of South Florida
- Wake Forest Health Sciences
- SUNY Upstate
- Washington University
- Beth Israel Deaconess
- University of Massachusetts
- Hospital for Special Care

as of 2/10/22
Checking Site Status Online

List of Participating Sites

Sites marked "Recruiting" are currently enrolling participants in regimen E.

Sites marked "Active, Not recruiting" are active in the platform (for example, they are following participants in regimens A-D) but are not enrolling new participants at this time. Most active sites are expected to start enrolling in regimen E soon.

<table>
<thead>
<tr>
<th>Site</th>
<th>State</th>
<th>Enrollment Status</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jefferson Weinberg ALS Center,</td>
<td>PA</td>
<td>Active, Not recruiting</td>
<td>Stephanie Hansen</td>
</tr>
<tr>
<td>Thomas Jefferson University</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lehigh Valley Health Network</td>
<td>PA</td>
<td>Recruiting</td>
<td>Andrew Orzel (610-402-9543)</td>
</tr>
<tr>
<td>Penn State Hershey</td>
<td>PA</td>
<td>Active, Not recruiting</td>
<td>Heidi Runk</td>
</tr>
</tbody>
</table>
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration: [QR Code]
ALS Link sign-up: [QR Code]

Upcoming Guest Speakers:
Feb 17th- Jim Caress, MD (Wake Forest, Winston-Salem NC)
March 3rd- Andrea Swenson, MD (University of Iowa, Iowa City IA)